Citations

Showing 10 of 108081 citations.

Risk of Second Primary Malignancy Associated with Cumulative Doses of Radioactive Iodine in Patients with Differentiated Thyroid Cancer
Toro-Tobón, David , Kawkgi, Omar EI, Toro-Tobon, David , Kawkgi, Omar E

Mayo Clinic

Clinical Thyroidology | April 10, 2023 | Volume: 35 | Issue: 4 | Pages: 154-156

10.1089/ct.2023;35.154-156 Get It

PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis
Moyo, Tamara K. , Kishtagari, Ashwin , Villaume, Matthew T. , McMahon, Brandon , Mohan, Sanjay , Stopczynski, Tess , Chen, Sheau‐Chiann , Fan, Run , Huo, Yuankai , Moon, Hyeonsoo , Tang, Yucheng , Bejan, Cosmin A. , Anderson, Ingrid , Rawling, Kyle , Simons, Rhea M. , Moncrief, Ashley , Caza, Rebekah , Dugger, Laura , Collins, Aunshka , Dudley, Channing V. , Byrne, Michael , Ayers, Gregory D. , Mason, Emily F. , Palmer, Jeanne , Michaelis, Laura C. , Mohan, Sanjay R , Childress, Merrida , Anderson, Ingrid , Rawling, Kyle , Simons, Rhea M , Moncrief, Ashley , Caza, Rebekah , Dugger, Laura , Collins, Aunshka , Dudley, Channing V , Ferrell, P Brent , Byrne, Michael , Strickland, Stephen Anthony , Ayers, Gregory D , Landman, Bennett A , Mason, Emily F , Mesa, Ruben , Palmer, Jeanne M , Michaelis, Laura C , Savona, Michael R , Chen, Sheau-Chiann , Kishtagari, Ashwin , Mesa, Ruben A. , Savona, Michael R.

Mayo Clinic

Clinical Cancer Research | April 10, 2023 | Volume: 29 | Issue: 13 | Pages: 2375-2384

10.1158/1078-0432.ccr-22-3192 | PMID 37036505 Get It

Abstract Purpose: Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce proliferation and induce apoptosis of JAK2V617F-mutant cell lines. Patients and Methods: In a phase I dose-escalation and -expansion study, we evaluated the safety and efficacy of a selective PI3Kδ inhibitor, umbralisib, in combination with ruxolitinib in patients with MF who had a suboptimal response or lost response to ruxolitinib. Enrolled subjects were required to be on a stable dose of ruxolitinib for ≥8 weeks and continue that MTD at study enrollment. The recommended dose of umbralisib in combination with ruxolitinib was determined using a modified 3+3 dose-escalation design. Safety, pharmacokinetics, and efficacy outcomes were evaluated, and spleen size was measured with a novel automated digital atlas. Results: Thirty-seven patients with MF (median age, 67 years) with prior exposure to ruxolitinib were enrolled. A total of 2 patients treated with 800 mg umbralisib experienced reversible grade 3 asymptomatic pancreatic enzyme elevation, but no dose-limiting toxicities were seen at lower umbralisib doses. Two patients (5%) achieved a durable complete response, and 12 patients (32%) met the International Working Group-Myeloproliferative Neoplasms Research and Treatment response criteria of clinical improvement. With a median follow-up of 50.3 months for censored patients, overall survival was greater than 70% after 3 years of follow-up. Conclusions: Adding umbralisib to ruxolitinib in patients was well tolerated and may resensitize patients with MF to ruxolitinib without unacceptable rates of adverse events seen with earlier generation PI3Kδ inhibitors. Randomized trials testing umbralisib in the treatment of MF should be pursued.
Review of management options for mantle cell lymphoma in pregnancy
Ng, Wern Lynn , Bock, Allison M. , Wang, Michael , Nowakowski, Grzegorz S. , Wang, Yucai , Jevremović, Dragan

Mayo Clinic

Leukemia & Lymphoma | April 10, 2023 | Volume: 64 | Issue: 6 | Pages: 1194-1198

10.1080/10428194.2023.2196592 | PMID 37035894 Get It

Carborane-Containing Hydroxamate MMP Ligands for the Treatment of Tumors Using Boron Neutron Capture Therapy (BNCT): Efficacy without Tumor Cell Entry
Flieger, Sebastian , Takagaki, Mao, Kondo, Natsuko , Lutz, M. , Gupta, Yash , Ueda, Hiroki , Moran, Graham R. , Kempaiah, Prakasha , Hosmane, Narayan S. , Becker, Daniel P. , Moran, Graham , Kempaiah, Prakasha , Hosmane, Narayan , Becker, Daniel P , Gupta, Yash , Lutz, Marlon R., Sakurai, Yoshinori , Suzuki, Minoru

Mayo Clinic

International Journal of Molecular Sciences | April 10, 2023 | Volume: 24 | Issue: 8 | Pages: 6973

10.3390/ijms24086973 | PMID 37108137 Get It

New carborane-bearing hydroxamate matrix metalloproteinase (MMP) ligands have been synthesized for boron neutron capture therapy (BNCT) with nanomolar potency against MMP-2, -9 and -13. New analogs are based on MMP inhibitor CGS-23023A, and two previously reported MMP ligands 1 (B1) and 2 (B2) were studied in vitro for BNCT activity. The boronated MMP ligands 1 and 2 showed high in vitro tumoricidal effects in an in vitro BNCT assay, exhibiting IC50 values for 1 and 2 of 2.04 × 10−2 mg/mL and 2.67 × 10−2 mg/mL, respectively. The relative killing effect of 1 to L-boronophenylalanine (BPA) is 0.82/0.27 = 3.0, and that of 2 is 0.82/0.32 = 2.6, whereas the relative killing effect of 4 is comparable to boronophenylalanine (BPA). The survival fraction of 1 and 2 in a pre-incubation boron concentration at 0.143 ppm 10B and 0.101 ppm 10B, respectively, were similar, and these results suggest that 1 and 2 are actively accumulated through attachment to the Squamous cell carcinoma (SCC)VII cells. Compounds 1 and 2 very effectively killed glioma U87 delta EGFR cells after BNCT. This study is noteworthy in demonstrating BNCT efficacy through binding to MMP enzymes overexpressed at the surface of the tumor cell without tumor cell penetration.
Inhibitory Synaptic Influences on Developmental Motor Disorders
Fogarty, Matthew J.

Mayo Clinic

International Journal of Molecular Sciences | April 10, 2023 | Volume: 24 | Issue: 8 | Pages: 6962

10.3390/ijms24086962 | PMID 37108127 Get It

During development, GABA and glycine play major trophic and synaptic roles in the establishment of the neuromotor system. In this review, we summarise the formation, function and maturation of GABAergic and glycinergic synapses within neuromotor circuits during development. We take special care to discuss the differences in limb and respiratory neuromotor control. We then investigate the influences that GABAergic and glycinergic neurotransmission has on two major developmental neuromotor disorders: Rett syndrome and spastic cerebral palsy. We present these two syndromes in order to contrast the approaches to disease mechanism and therapy. While both conditions have motor dysfunctions at their core, one condition Rett syndrome, despite having myriad symptoms, has scientists focused on the breathing abnormalities and their alleviation—to great clinical advances. By contrast, cerebral palsy remains a scientific quagmire or poor definitions, no widely adopted model and a lack of therapeutic focus. We conclude that the sheer abundance of diversity of inhibitory neurotransmitter targets should provide hope for intractable conditions, particularly those that exhibit broad spectra of dysfunction—such as spastic cerebral palsy and Rett syndrome.
Relationship Functioning and Gut Microbiota Composition among Older Adult Couples
Cheng, Qiwen , Krajmalnik‐Brown, Rosa , DiBaise, John K. , Maldonado, Juan , Guest, M. Aaron , Todd, Michael , Langer, Shelby L.

Mayo Clinic

International Journal of Environmental Research and Public Health | April 10, 2023 | Volume: 20 | Issue: 8 | Pages: 5435

10.3390/ijerph20085435 | PMID 37107717 Get It

An emerging area of research extends work on couple functioning and physical health to gut health, a critical marker of general health and known to diminish with age. As a foray into this area, we conducted a pilot study to (1) determine the feasibility of remote data collection, including a fecal sample, from older adult couples, (2) examine within-couple concordance in gut microbiota composition, and (3) examine associations between relationship functioning and gut microbiota composition. Couples (N = 30) were recruited from the community. The participants’ demographic characteristics were as follows: M (SD) age = 66.6 (4.8), 53% female, 92% White, and 2% Hispanic. Two of the couples were same-sex. All 60 participants completed self-report measures and supplied a fecal sample for microbiome analysis. Microbial DNA was extracted from the samples, and the 16S rRNA gene V4 region was amplified and sequenced. The results indicated that individuals shared more similar gut microbial composition with their partners than with others in the sample, p < 0.0001. In addition, individuals with better relationship quality (greater relationship satisfaction and intimacy and less avoidant communication) had greater microbial diversity, p < 0.05, a sign of healthier gut microbiota. Further research with a larger and more diverse sample is warranted to elucidate mechanisms.
Partial Inhibition of Complex I Restores Mitochondrial Morphology and Mitochondria-ER Communication in Hippocampus of APP/PS1 Mice
Panes, Jessica , Nguyen, Thi Kim Oanh , Gao, Huanyao , Christensen, Trace , Trushin, Sergey , Salisbury, Jeffrey L., Fuentealba, Jorge , Trushina, Eugenia , Stojakovic, Andrea , Gao, Huanyao , Trushina, Eugenia

Mayo Clinic

Cells | April 10, 2023 | Volume: 12 | Issue: 8 | Pages: 1111

10.3390/cells12081111 | PMID 37190020 Get It

Alzheimer’s disease (AD) has no cure. Earlier, we showed that partial inhibition of mitochondrial complex I (MCI) with the small molecule CP2 induces an adaptive stress response, activating multiple neuroprotective mechanisms. Chronic treatment reduced inflammation, Aβ and pTau accumulation, improved synaptic and mitochondrial functions, and blocked neurodegeneration in symptomatic APP/PS1 mice, a translational model of AD. Here, using serial block-face scanning electron microscopy (SBFSEM) and three-dimensional (3D) EM reconstructions combined with Western blot analysis and next-generation RNA sequencing, we demonstrate that CP2 treatment also restores mitochondrial morphology and mitochondria-endoplasmic reticulum (ER) communication, reducing ER and unfolded protein response (UPR) stress in the APP/PS1 mouse brain. Using 3D EM volume reconstructions, we show that in the hippocampus of APP/PS1 mice, dendritic mitochondria primarily exist as mitochondria-on-a-string (MOAS). Compared to other morphological phenotypes, MOAS have extensive interaction with the ER membranes, forming multiple mitochondria-ER contact sites (MERCS) known to facilitate abnormal lipid and calcium homeostasis, accumulation of Aβ and pTau, abnormal mitochondrial dynamics, and apoptosis. CP2 treatment reduced MOAS formation, consistent with improved energy homeostasis in the brain, with concomitant reductions in MERCS, ER/UPR stress, and improved lipid homeostasis. These data provide novel information on the MOAS-ER interaction in AD and additional support for the further development of partial MCI inhibitors as a disease-modifying strategy for AD.
A Comprehensive Review of the Genetic and Epigenetic Contributions to the Development of Fibromyalgia
Ovrom, Erik A. , Mostert, Karson A., Khakhkhar, Shivani, McKee, Daniel P. , Yang, Padao, Her, Yeng F , Mostert, Karson

Mayo Clinic

Biomedicines | April 10, 2023 | Volume: 11 | Issue: 4 | Pages: 1119

10.3390/biomedicines11041119 | PMID 37189737 Get It

This narrative review summarizes the current knowledge of the genetic and epigenetic contributions to the development of fibromyalgia (FM). Although there is no single gene that results in the development of FM, this study reveals that certain polymorphisms in genes involved in the catecholaminergic pathway, the serotonergic pathway, pain processing, oxidative stress, and inflammation may influence susceptibility to FM and the severity of its symptoms. Furthermore, epigenetic changes at the DNA level may lead to the development of FM. Likewise, microRNAs may impact the expression of certain proteins that lead to the worsening of FM-associated symptoms.
LRP1 in vascular mural cells modulates cerebrovascular integrity and function in the presence of APOE4
Oue, Hiroshi , Yamazaki, Yu , Qiao, Wenhui , Yuanxin, Chen, Ren, Yingxue , Kurti, Aishe, Shue, Francis , Parsons, Tammee M., Perkerson, Ralph B., Kawatani, Keiji , Wang, Ni , Starling, Skylar C , Mosneag, Ioana‐Emilia , Aikawa, Tomonori , Holm, Marie‐Louise , Liu, Chia‐Chen , Inoue, Yasuteru , Sullivan, Patrick M. , Asmann, Yan W. , Bu, Guojun , Kanekiyo, Takahisa , Liu, Chia-Chen , Bu, Guojun , Shue, Francis , Yuanxin, Chen, Roy, Bhaskar, Kim, Betty Y.S. , Yamazaki, Yu

Mayo Clinic

JCI Insight | April 9, 2023 | Volume: 8 | Issue: 7 | Pages: No page available

10.1172/jci.insight.163822 | PMID 37036005 Get It

Cerebrovasculature is critical in maintaining brain homeostasis; its dysregulation often leads to vascular cognitive impairment and dementia (VCID) during aging. VCID is the second most prevalent cause of dementia in the elderly, after Alzheimer’s disease (AD), with frequent cooccurrence of VCID and AD. While multiple factors are involved in the pathogenesis of AD and VCID, APOE4 increases the risk for both diseases. A major apolipoprotein E (apoE) receptor, the low-density lipoprotein receptor-related protein 1 (LRP1), is abundantly expressed in vascular mural cells (pericytes and smooth muscle cells). Here, we investigated how deficiency of vascular mural cell LRP1 affects the cerebrovascular system and cognitive performance using vascular mural cell–specific Lrp1 -KO mice ( smLrp1 –/– ) in a human APOE3 or APOE4 background. We found that spatial memory was impaired in the 13- to 16-month-old APOE4 smLrp1 –/– mice but not in the APOE3 smLrp1 –/– mice, compared with their respective littermate control mice. These disruptions in the APOE4 smLrp1 –/– mice were accompanied with excess paravascular glial activation and reduced cerebrovascular collagen IV. In addition, blood-brain barrier (BBB) integrity was disrupted in the APOE4 smLrp1 –/– mice. Together, our results suggest that vascular mural cell LRP1 modulates cerebrovasculature integrity and function in an APOE genotype–dependent manner.
Mast cell activation: beyond histamine and tryptase
Theoharides, Theoharis C. , Perlman, Adam , Twahir, Assma, Kempuraj, Duraisamy , Perlman, Adam

Mayo Clinic

Expert Review of Clinical Immunology | April 8, 2023 | Volume: 19 | Issue: 6 | Pages: 639-654

10.1080/1744666x.2023.2200936 | PMID 37029958 Get It